Left atrium decompression devices across the spectrum of ejection fraction in heart failure: an updated systematic review and meta-regression analysis
Background In patients affected by heart failure (HF) with reduced ejection fraction (HFrEF), pharmacological treatments have been proven to alleviate symptoms and improve prognosis, while no treatment other than sodium-glucose co-transporter-2 inhibitors have demonstrated significant effects in HF with preserved ejection fraction (HFpEF). Left atrium decompression devices (LADd) have been recently investigated as a new interventional approach in patients with HFpEF. Objectives To assess the efficacy of LADd on soft endpoints in HF patients across the spectrum of ejection fraction. Methods PubMed and Web of Science were searched without restrictions from inception to 28 May 2022 to identify valuable articles. The studies that met the inclusion criteria were analyzed. The prespecified main outcomes were the change from baseline in 6-min walking distance (6MWD), NYHA class and health-related quality of life (HRQoL). Secondary outcomes were reduction in HF hospitalizations, echocardiographic, and hemodynamic parameters. Results Eleven studies, with a total of 547 patients, were included. LADd significantly improved 6MWD by 43.95 m (95% CI 29.64–58.26 m), decreased NYHA class by 0.93 (95% CI 1.20–0.67), and improved HRQoL questionnaire by 20.45 points (95% CI 13.77–27.14) with better results for all outcomes in patients with lower EFs. Conclusion The present meta-analysis suggests that LADd are favorable in improving 6MWD, NYHA class, and HRQoL in HF across a wide spectrum of ejection fraction, with better outcomes in patients with lower EFs. Trial registration CRD42022336077, URL: https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=336077..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:28 |
|---|---|
| Enthalten in: |
Heart failure reviews - 28(2023), 5 vom: 10. Mai, Seite 1151-1161 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Basile, Christian [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Health-related quality of life outcomes |
|---|
| Anmerkungen: |
© The Author(s) 2023 |
|---|
| doi: |
10.1007/s10741-023-10317-2 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR052639487 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR052639487 | ||
| 003 | DE-627 | ||
| 005 | 20230805064708.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230805s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s10741-023-10317-2 |2 doi | |
| 035 | |a (DE-627)SPR052639487 | ||
| 035 | |a (SPR)s10741-023-10317-2-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Basile, Christian |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Left atrium decompression devices across the spectrum of ejection fraction in heart failure: an updated systematic review and meta-regression analysis |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s) 2023 | ||
| 520 | |a Background In patients affected by heart failure (HF) with reduced ejection fraction (HFrEF), pharmacological treatments have been proven to alleviate symptoms and improve prognosis, while no treatment other than sodium-glucose co-transporter-2 inhibitors have demonstrated significant effects in HF with preserved ejection fraction (HFpEF). Left atrium decompression devices (LADd) have been recently investigated as a new interventional approach in patients with HFpEF. Objectives To assess the efficacy of LADd on soft endpoints in HF patients across the spectrum of ejection fraction. Methods PubMed and Web of Science were searched without restrictions from inception to 28 May 2022 to identify valuable articles. The studies that met the inclusion criteria were analyzed. The prespecified main outcomes were the change from baseline in 6-min walking distance (6MWD), NYHA class and health-related quality of life (HRQoL). Secondary outcomes were reduction in HF hospitalizations, echocardiographic, and hemodynamic parameters. Results Eleven studies, with a total of 547 patients, were included. LADd significantly improved 6MWD by 43.95 m (95% CI 29.64–58.26 m), decreased NYHA class by 0.93 (95% CI 1.20–0.67), and improved HRQoL questionnaire by 20.45 points (95% CI 13.77–27.14) with better results for all outcomes in patients with lower EFs. Conclusion The present meta-analysis suggests that LADd are favorable in improving 6MWD, NYHA class, and HRQoL in HF across a wide spectrum of ejection fraction, with better outcomes in patients with lower EFs. Trial registration CRD42022336077, URL: https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=336077. | ||
| 650 | 4 | |a Heart failure |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Interatrial shunting |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Meta-analysis |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Interventional heart failure treatment |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Health-related quality of life outcomes |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Paolillo, Stefania |0 (orcid)0000-0003-4683-0993 |4 aut | |
| 700 | 1 | |a Gargiulo, Paola |4 aut | |
| 700 | 1 | |a Marzano, Federica |4 aut | |
| 700 | 1 | |a Dellegrottaglie, Santo |4 aut | |
| 700 | 1 | |a Abbate, Vincenza |4 aut | |
| 700 | 1 | |a Ambrosio, Antonio |4 aut | |
| 700 | 1 | |a Carbone, Francesca |4 aut | |
| 700 | 1 | |a Dell’Aversana, Simona |4 aut | |
| 700 | 1 | |a Esposito, Immacolata |4 aut | |
| 700 | 1 | |a Fierro, Maria Francesca |4 aut | |
| 700 | 1 | |a Perrone-Filardi, Pasquale |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Heart failure reviews |d Dordrecht [u.a.] : Springer Science + Business Media B.V, 1996 |g 28(2023), 5 vom: 10. Mai, Seite 1151-1161 |w (DE-627)SPR012861839 |w (DE-600)2006431-7 |x 1573-7322 |7 nnns |
| 773 | 1 | 8 | |g volume:28 |g year:2023 |g number:5 |g day:10 |g month:05 |g pages:1151-1161 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s10741-023-10317-2 |z kostenfrei |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 951 | |a AR | ||
| 952 | |d 28 |j 2023 |e 5 |b 10 |c 05 |h 1151-1161 | ||